Harbour BioMed's Patent Success and Legal Journey
Harbour BioMed (HKEX: 02142) is making waves in the biopharmaceutical industry with significant developments in its patent protection strategies. The recent affirmation of its patent by the China National Intellectual Property Administration (CNIPA) marks a crucial milestone, ensuring the preservation of its innovative technologies, particularly in the fields of immunology and oncology.
CNIPA Upholds Harbour BioMed's Patent
Following a challenge from Biocytogen Pharmaceuticals, who filed an invalidation request against Harbour BioMed's patent titled 'Binding Molecule,' CNIPA issued a final decision confirming the validity of this patent. This ruling is pivotal for Harbour BioMed, as it protects their unique method for generating fully human heavy chain-only antibodies (HCAbs) utilizing transgenic animals.
The Legal Battle Unfolds
In an attempt to safeguard its innovations, Harbour BioMed took action by filing a patent infringement lawsuit against Biocytogen, asserting that their RenNano platform violates the HCAb Patent. Biocytogen's response involved questioning the jurisdiction of the Shanghai Intellectual Property Court, escalating the issue through the legal system. However, on May 27, 2025, the Supreme People's Court reaffirmed the Shanghai court's authority over the case, allowing Harbour BioMed to proceed with its claims.
A Vision for the Future
Dr. Jingsong Wang, the Founder and CEO of Harbour BioMed, expressed his enthusiasm regarding the recent CNIPA decision, emphasizing the importance of intellectual property in fostering innovation. He remarked on the significance of their extensive global patent portfolio, which supports ongoing research and development efforts, ultimately leading to breakthrough therapies for patients worldwide.
Innovative Technology at the Core
Harbour BioMed distinguishes itself through its proprietary Harbour Mice technology, enabling the development of fully human monoclonal antibodies. This unique platform facilitates the creation of HCAb-based therapies, allowing for cutting-edge advancements in treating various medical conditions. The incorporation of advanced technologies like HBICE, a bispecific antibody platform, and HBICA, enhances the company's ability to deliver impactful treatments.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is dedicated to pioneering advancements in antibody therapeutics, particularly within immunology and oncology fields. By focusing on strategic collaborations and selective acquisitions, the company is enhancing its development pipeline, ensuring it stays at the forefront of biopharmaceutical innovation.
Frequently Asked Questions
What is the significance of the CNIPA decision for Harbour BioMed?
The CNIPA decision validates Harbour BioMed's patent, reinforcing its position in the biopharmaceutical industry and protecting its innovative technologies.
How does Harbour BioMed's technology differ from traditional methods?
Harbour BioMed's unique Harbour Mice platform generates fully human antibodies, providing an innovative approach to antibody therapeutics that surpasses traditional methods.
What are HCAbs and why are they important?
HCAbs are fully human heavy chain-only antibodies that offer advantages in therapeutic applications, particularly in oncology and immunology.
What challenges did Harbour BioMed face in its legal battle?
Harbour BioMed confronted jurisdictional challenges from Biocytogen, ultimately resolved in its favor, allowing the infringement lawsuit to advance.
What future plans does Harbour BioMed have for its technology?
Harbour BioMed aims to leverage its patented technologies to accelerate the development of transformative therapies in collaboration with global partners.
